Page 29 - Professor Mark News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Salt Lake City, Utah--(Newsfile Corp. - May 26, 2021) -  Today, President Kristy Hunt of Green Star Products, Inc. (OTC PINK: GSPI)

 E-Mail Credit: Trevor Fristoe and Mark van Kleunen Invasive alien plants are plant species that grow in an environment outside their native habitat. If they successfully establish self-sustaining populations in these new environments - an event called "naturalization" - they can have considerable negative impacts on local ecosystems, economies, and societies. But not all alien plant species are equally effective in invading new habitats. Therefore, an international team of scientists, headed by Konstanz-based biologist Professor Mark van Kleunen, investigated different types of "invasivenes...

Covid-19: Here's when to expect next week's summer re-opening decisions Cabinet will meet on Friday this week. By Christina Finn Saturday 22 May 2021, 6:30 AM 3 hours ago 17,870 Views 10 Comments Image: PA Image: PA THE GOVERNMENT WILL next week give a detailed and “comprehensive” statement on plans for travel, aviation, entertainment, sport and mandatory hotel quarantine as part of the next phase of reopening for June and July. Micheál...

Two repurposed drugs and a blue dye show potential as SARS-CoV-2 entry inhibitors A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19). The ongoing pandemic of COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a health emergency that necessitates the continued use of vaccines, but also the development of new drugs to prevent or treat thi...

Published: Apr 21, 2021 - Backed by leading healthcare investors including SV Health Investors - Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”). The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technolog...